Biomerieux Inc.

Biomerieux Inc., operating through its Biomerieux, Inc. Division as Vitek Systems, Inc., is a global leader in in vitro diagnostics and microbiological testing solutions. The company specializes in manufacturing advanced diagnostic equipment, reagents, test kits, and clinical laboratory technologies for medical applications. Biomerieux provides specialized diagnostic platforms and services to multiple federal healthcare agencies, positioning itself as a critical supplier of microorganism identification, antibiotic susceptibility testing, and molecular pathogen detection capabilities to the federal government. The company's diagnostic solutions support infectious disease testing, pathogen detection, and overall clinical laboratory operations across the government healthcare sector.

Biomerieux Inc. has received numerous prime federal contract awards totaling millions of dollars, primarily from the Department of Veterans Affairs across multiple Veterans Integrated Service Networks, as well as from the Indian Health Service, Defense Health Agency, National Institutes of Health, Food and Drug Administration, and other federal agencies. The company has provided comprehensive diagnostic equipment and supplies including its proprietary VITEK, BioFire, and VIDAS diagnostic platforms, along with associated reagents, test kits, consumables, and maintenance services. Specific deliverables have included BioFire reagents and test kits, VITEK microorganism identification and antibiotic susceptibility testing systems, VIDAS immunoassay systems, automated blood culture testing equipment, multiplex PCR reagents, molecular pathogen detection solutions, and extended warranty and preventative maintenance agreements for laboratory analyzers. Delivery orders and purchase orders have ranged from thousands to millions of dollars, with ceiling values across individual contracts spanning from $12,000 to over $3.5 million. Contract types have included firm fixed-price delivery orders, blanket purchase agreement calls, purchase orders, and service agreements. The company has consistently received awards without set-aside designations, reflecting its status as a specialized sole-source provider for proprietary diagnostic technologies. Notable federal partners have included VISN 1, VISN 2, VISN 4, VISN 5, VISN 6, VISN 8, VISN 9, VISN 10, VISN 12, VISN 15, VISN 16, VISN 17, VISN 19, VISN 21, VISN 23, the Indian Health Service, the Defense Health Agency, the Military Sealift Command, the National Oceanic and Atmospheric Administration, and various other federal agencies. The company has also provided diagnostic equipment and services through General Services Administration Federal Supply Schedule contracts and multiple award schedule vehicles, enabling government agencies to efficiently access its specialized solutions.

Biomerieux Inc. has received federal grant sub-awards supporting laboratory equipment repair services. The company received a federal grant sub-award in May 2022 for the provision of repair services for laboratory equipment, demonstrating its capability to support federal healthcare operations beyond direct contract procurement. This sub-grant award indicates Biomerieux's role in maintaining critical laboratory infrastructure for government agencies, complementing its primary mission of supplying diagnostic equipment and consumables. While the sub-grant activity appears limited compared to the extensive contract portfolio, it reflects the company's broader engagement in supporting federal laboratory operations through multiple procurement mechanisms.

Biomerieux Inc. maintains an extensive portfolio of federal contract Indefinite Delivery Vehicles with various Department of Veterans Affairs Veterans Integrated Service Networks and other federal agencies, with total ceiling values exceeding $30 million. These IDVs include both Blanket Purchase Agreements and Indefinite Delivery Contracts under the GSA Federal Supply Schedule for In Vitro Diagnostics, Reagents, and Test Kits (FSS-65-VII) and other laboratory equipment schedules. Notable IDVs include a $13 million BPA with VISN 21 for Film Array Laboratory Test System cost-per-test services, a $5.15 million BPA with VISN 5 for virus, bacteria, and parasite detection reagents and test kits, a $4.56 million BPA with VISN 15 for VITEK supplies and maintenance services, a $3.53 million IDC with VISN 6 for automated blood culture analyzer systems and consumables, and a $2.21 million BPA with VISN 10 for BioFire test kits. Additional IDVs include agreements with VISN 2, VISN 4, VISN 17, VISN 21, the Indian Health Service, and the Defense Health Agency for specialized diagnostic equipment, reagents, maintenance services, and technical support. These contract vehicles enable federal healthcare agencies to issue task orders and delivery orders on an as-needed basis, facilitating efficient procurement of critical diagnostic capabilities. The IDVs typically span multiple years, with performance periods extending through 2026 to 2030, ensuring sustained access to Biomerieux's specialized diagnostic platforms and consumables. Task orders issued under these IDVs have ranged from tens of thousands to millions of dollars, collectively representing substantial government investment in advanced microbiological diagnostic capabilities through established contract vehicles.